IL165051A0 - New compounds useful for the treatment of obesity,type II diabetes and cns disorders - Google Patents

New compounds useful for the treatment of obesity,type II diabetes and cns disorders

Info

Publication number
IL165051A0
IL165051A0 IL16505104A IL16505104A IL165051A0 IL 165051 A0 IL165051 A0 IL 165051A0 IL 16505104 A IL16505104 A IL 16505104A IL 16505104 A IL16505104 A IL 16505104A IL 165051 A0 IL165051 A0 IL 165051A0
Authority
IL
Israel
Prior art keywords
obesity
diabetes
treatment
type
compounds useful
Prior art date
Application number
IL16505104A
Other languages
English (en)
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/xx
Priority claimed from SE0202181A external-priority patent/SE0202181D0/xx
Priority claimed from SE0202908A external-priority patent/SE0202908D0/xx
Priority claimed from SE0300357A external-priority patent/SE0300357D0/xx
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of IL165051A0 publication Critical patent/IL165051A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL16505104A 2002-06-20 2004-11-04 New compounds useful for the treatment of obesity,type II diabetes and cns disorders IL165051A0 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (sv) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (sv) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (sv) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (sv) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number Publication Date
IL165051A0 true IL165051A0 (en) 2005-12-18

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16505104A IL165051A0 (en) 2002-06-20 2004-11-04 New compounds useful for the treatment of obesity,type II diabetes and cns disorders

Country Status (13)

Country Link
EP (1) EP1513828A1 (zh)
CN (1) CN1662521A (zh)
AU (1) AU2003243091A1 (zh)
BR (1) BR0311952A (zh)
CA (1) CA2486989A1 (zh)
EA (2) EA011581B1 (zh)
IL (1) IL165051A0 (zh)
MX (1) MXPA04012914A (zh)
NO (1) NO20050294L (zh)
NZ (3) NZ536600A (zh)
RS (1) RS111204A (zh)
SG (1) SG156524A1 (zh)
WO (1) WO2004000828A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307919T3 (es) 2002-03-27 2008-12-01 Glaxo Group Limited Derivados de quinolina y su uso como ligandos de 5-ht6.
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
BRPI0417833A (pt) * 2003-12-19 2007-04-17 Biovitrum Ab novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
TWI380816B (zh) * 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (es) * 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
US7582767B2 (en) 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
EP1907384A2 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
KR20140033237A (ko) 2005-10-07 2014-03-17 엑셀리시스, 인코포레이티드 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법
WO2007051735A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
CA2654822A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
CN101472884A (zh) 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其用途
JP2009541248A (ja) 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホンアミジルテトラリン誘導体及びそれらの使用
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2012154194A1 (en) * 2011-05-09 2012-11-15 Forma Tm, Llc Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
WO1994021619A1 (en) * 1993-03-16 1994-09-29 Pfizer Inc. Naphthalene derivatives
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
WO2001085722A1 (en) * 2000-05-05 2001-11-15 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
MXPA02010763A (es) * 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
MXPA03003397A (es) * 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.
PL366619A1 (en) * 2001-05-11 2005-02-07 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
EP1401813B1 (en) * 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
EA008476B1 (ru) * 2001-06-11 2007-06-29 Биовитрум Аб Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii

Also Published As

Publication number Publication date
AU2003243091A1 (en) 2004-01-06
BR0311952A (pt) 2005-04-19
EA200500054A1 (ru) 2005-06-30
EA200600975A1 (ru) 2006-10-27
CA2486989A1 (en) 2003-12-31
NZ536600A (en) 2007-08-31
WO2004000828A1 (en) 2003-12-31
NZ552283A (en) 2008-07-31
MXPA04012914A (es) 2005-03-31
NZ552282A (en) 2008-07-31
EA011581B1 (ru) 2009-04-28
CN1662521A (zh) 2005-08-31
RS111204A (en) 2006-12-15
EA008835B1 (ru) 2007-08-31
SG156524A1 (en) 2009-11-26
NO20050294L (no) 2005-02-04
EP1513828A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
IL165051A0 (en) New compounds useful for the treatment of obesity,type II diabetes and cns disorders
HK1066790A1 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
HK1068335A1 (en) Novel arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
IL165257A0 (en) 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obestity anddyslipidemia
SI1474416T1 (sl) Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj
AU2003207717B9 (en) 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
EP1625207A4 (en) COMPOUNDS FOR THE TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS
IL209842A0 (en) Compounds for the treatment of metabolic disorders
AP2005003274A0 (en) Thiazole compounds for the treatment of neurodegenerative disorders
EP1534074A4 (en) POLYTHERAPY FOR THE TREATMENT OF OBESITY
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
AU2003282156A8 (en) Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type ii diabetes
IL165242A0 (en) Treatment for diabetes
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
ZA200409030B (en) New compounds useful for the treatment of obesity,type ii diabetes and CNS disorders.
AU2003239967A1 (en) Compound for the treatment of cns disorders
AU2003243214A1 (en) Salts of bis-arylsulfones for the treatment of cns disorders
HRP20041159A2 (en) Combination for the treatment of airway disorders